These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 1311061)

  • 1. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
    Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
    Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance].
    Mitsudomi T; Oyama T; Gazdar AF; Minna JD; Okabayashi K; Shirakusa T
    Nihon Geka Gakkai Zasshi; 1992 Sep; 93(9):944-7. PubMed ID: 1361656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.
    Mitsudomi T; Steinberg SM; Oie HK; Mulshine JL; Phelps R; Viallet J; Pass H; Minna JD; Gazdar AF
    Cancer Res; 1991 Sep; 51(18):4999-5002. PubMed ID: 1654209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer.
    Hensel CH; Xiang RH; Sakaguchi AY; Naylor SL
    Oncogene; 1991 Jun; 6(6):1067-71. PubMed ID: 1648702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
    Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
    Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
    Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
    Wu WG; Soria JC; Wang L; Kemp BL; Mao L
    Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
    Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
    Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
    Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
    Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of features of human lung cancer cell lines and their corresponding tumors.
    Wistuba II; Bryant D; Behrens C; Milchgrub S; Virmani AK; Ashfaq R; Minna JD; Gazdar AF
    Clin Cancer Res; 1999 May; 5(5):991-1000. PubMed ID: 10353731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.